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were found in patients with higher ETDRS levels (p = 0.04). 
In a multivariable linear regression model, CRAE was associ-
ated with macular ganglion cell layer thickness (coefficient 
0.27 per micrometre, p < 0.01), and CRVE was correlated with 
macular retinal thickness (coefficient –0.07 per micrometre, 
p = 0.04) and retinal nerve fibre layer thickness at the optic 
disc (coefficient 0.32 per micrometre, p < 0.01).  Conclusion: 
Retinal vessel calibre was independently associated with 
structural changes of the neuroretina in patients with no or 
early DR.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 More than 382 million people have diabetes mellitus 
(DM), and the number affected is increasing dramatical-
ly with an expected number of patients of 592 million by 
2035  [1] . Diabetic retinopathy (DR) is a frequent and po-
tentially blinding ocular complication and a leading cause 
of vision loss in working-age people  [2] . For many years 
 Key Words 
 Retinal vessel calibre · Neurodegeneration · Type 2 diabetes 
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 Abstract 
 Purpose: To investigate the correlation between retinal ves-
sel calibre and measurements of neurodegeneration in pa-
tients with type 2 diabetes (T2D) and no or early diabetic 
retinopathy (DR).  Methods: Baseline data on 440 patients 
with T2D from the EUROCONDOR clinical trial were used. DR 
was graded according to the Early Treatment of Diabetic Ret-
inopathy Study (ETDRS) scale, and patients with ETDRS levels 
10–35 were included. Retinal vessel diameters were mea-
sured by semi-automatic software. Calibres were summa-
rized into central retinal artery and vein equivalents (CRAE 
and CRVE).  Results: Median age and diabetes duration were 
64.0 and 10.3 years, respectively. ETDRS levels were 10 
(42.3%), 20 (27.5%) and 35 (30.2%). The median CRAE and 
CRVE were 146.7 and 215.3 μm, respectively. CRAE did not 
differ according to ETRDS level (p = 0.12), but wider CRVE 
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DR has been described as a microvascular complication, 
but more recent findings suggest that neurodegeneration 
plays an important role in the pathogenesis of DR  [3–5] . 
Different neurogenic factors have been investigated, and 
the interaction between neural activity and regulation of 
blood flow, described as the neurovascular coupling, has 
been suggested to be involved in the mechanism of the 
disease  [6] .
 Retinal vessel calibre can be measured non-invasively 
by semi-automatic software  [7, 8] . Several studies have 
found a relation between retinal vessel calibre and micro- 
and macrovascular complications in patients with DM 
 [9–13] , and in a prospective study it was demonstrated 
that narrower arteriolar and wider retinal venular diam-
eters predict long-term nephropathy, peripheral neurop-
athy and proliferative DR  [14] .
 Retinal neurodegeneration can be assessed clinically. 
Multifocal electroretinography (mf-ERG) examines 
functional parameters, while optical coherence tomogra-
phy (OCT) measures the structural composition of the 
neuroretina. 
 Retinal vessel calibre analysis combined with func-
tional and structural examinations of retinal neurodegen-
eration can reveal new aspects of the complex neurovas-
cular interaction. Only a few clinical studies that included 
retinal vessel calibre measurements have investigated 
neurovascular characteristics in patients with diabetes 
 [15–18] . However, these studies were limited by a low 
sample size or did not investigate the association between 
retinal vasculature and parameters related to neurode-
generation as primary end point. 
 Given that retinal vascular calibre changes are an early, 
and often even preclinical, sign of vascular damage in di-
abetes  [14] , we speculate that the subtle interplay between 
vascular and neurogenic damage may be an early indica-
tor of retinal impairment. Hence, the aim of the present 
study was to investigate the correlations between retinal 
vessel calibre and neurodegeneration measurements in 
patients with type 2 DM (T2DM) and no or minimal DR.
 Methods 
 Study Population 
 The European Consortium for the Early Treatment of Diabetic 
Retinopathy [EUROCONDOR, NCT01726075 (278040)] is a mul-
ticentre, 2-year prospective, interventional, phase II–III, random-
ized controlled clinical trial  [6] . The primary objective was to as-
sess the efficacy of topically administered neuroprotective drugs 
(somatostatin and brimonidine) in order to prevent or arrest neu-
rodegenerative changes. Baseline data of 449 patients with T2DM 
was obtained between February 2013 and February 2014 at 11 Eu-
ropean sites. One study eye was identified in each patient. Only 
eyes with no or minimal DR (Early Treatment of Diabetic Reti-
nopathy Study, ETDRS, levels 10, 20 and 35) were included. In ad-
dition, inclusion criteria were duration of T2DM for at least 5 years 
and age between 45 and 75 years. Conversely, exclusion criteria 
were previous laser photocoagulation, retinal diseases that cause 
degeneration (e.g. glaucoma) and refractive error more than or 
equal to ±5 dpt. Eyes with blurred ocular media or inadequate pu-
pil dilatation that prevented good-quality fundus photography 
were excluded. Patients with renal failure or HbA 1c >86 mmol/mol 
in the previous 6 months were also excluded. 
 The study was approved by the European Commission (FP7-
HEALTH-2011) and was conducted in accordance with the prin-
ciples of the Helsinki II Declaration. Approval from the local sci-
entific ethical committees of each centre was obtained, and all pa-
tients gave written informed consent.
 Baseline Examinations 
 Examinations were performed according to the EUROCON-
DOR protocol and by certified technicians only. A full medical 
history including duration of T2DM and information about pres-
ence of any diabetic complications such as nephropathy and neu-
ropathy was obtained from medical records. Best-corrected visual 
acuity was measured, and a full ophthalmic examination was per-
formed. 
 Laboratory tests included the measurements of HbA 1c , choles-
terol, triglyceride, creatinine, glomerular filtration rate, albumin-
uria and the albumin/creatinine ratio. Furthermore, blood pres-
sure, height and weight were measured, and the body mass index 
was calculated. 
 Identification of the study eye, and gradings of colour fundus 
photographs, OCT and mf-ERG were done by a central reading 
centre (the Coimbra Ophthalmology Reading Centre).
 Fundus Examination 
 Mydriatic Topcon cameras (i.e. TRC-50IA, -50IX, -50EX, -50DX, 
-50DX Type IA and NW6S, Topcon, Tokyo, Japan) and a Zeiss cam-
era (FF450 PLUS IR, Carl Zeiss Meditec, Jena, Germany) were used 
to acquire 30- to 35-degree modified 7-field colour fundus photo-
graphs of both eyes after pupillary dilatation with tropicamide (10 
mg/ml) and phenylephrine (10%). Fields 1 and 3 were modified from 
the 7 ETDRS standard fields to include the centre of the macula. The 
level of DR was graded according to the ETDRS protocol  [19] .
 Structural Neurodegeneration 
 Topcon 3D OCT-2000 Spectral Domain OCT (Topcon; avail-
able at 4 clinical sites) and Zeiss Cirrus HD-OCT (Carl Zeiss Med-
itec; available at 7 clinical sites) were used to measure the macular 
retinal thickness, the macular ganglion cell layer (GCL) thickness 
and the retinal nerve fibre layer (RNFL) thickness at the optic disc. 
Different scan protocols and segmentation algorithms between in-
struments were used as previously documented  [20] . 
 To examine the differences between Topcon (n = 162) and 
Zeiss equipment (n = 278), we tested for the mean values of macu-
lar retinal thickness, macular GCL thickness and RNFL thickness 
at the optic disc. Patients who were examined by Zeiss OCT had a 
higher macular retinal thickness (265.20 vs. 238.62 μm, p < 0.01) 
and macular GCL (79.21 vs. 66.19 μm, p < 0.01) but a lower RNFL 
thickness at the optic disc (89.08 vs. 95.99 μm, p < 0.01). In order 
to address the differences, a conversion factor (mean Zeiss value 
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divided by mean Topcon value) was then added for Topcon mea-
surements throughout the analysis (given that Topcon was used 
only at 4 sites). Conversion factors were 1.11, 1.20 and 0.93 for 
macular retinal thickness, macular GCL thickness and RNFL 
thickness at the optic disc, respectively. 
 Functional Neurodegeneration 
 A RETI-scan mf-ERG system (Roland Consult, Brandenburg 
a.d. Havel, Germany) was used to measure implicit time and am-
plitudes of rings 1–6. The examined retinal area equivalent to 46.4° 
was arranged in 103 hexagons and divided into 6 rings, ring 1 being 
the central area. mf-ERG examination was performed based on the 
International Society for Clinical Electrophysiology of Vision 
standard for clinical mf-ERG  [21] . 
 Retinal Vessel Calibre Analysis 
 Modified field 1 images including the optic disc of the study eye 
were analysed with semi-automatic software (IVAN, Department 
of Ophthalmology Visual Science, University of Wisconsin, Mad-
ison, Wis., USA). The software automatically detected the optic 
disc and traced vessel diameter in a zone 0.5–1.0 disc diameters 
from the disc margin. Calibres were summarized into central reti-
nal artery and vein equivalents (CRAE and CRVE) according to 
the ‘Big 6 formula’ that included only the 6 largest arterioles and 
venules  [7] . One certified grader (U.F.-O.) performed the retinal 
vascular calibre analysis of the study eye according to a validated 
protocol  [8, 22] . 
 Statistical Methods 
 Statistical analyses were performed with STATA 14 (StataCorp 
LP, College Station, Tex., USA), and a p value <0.05 was consid-
ered statistically significant. Categorical data were presented as 
percentages, and continuous data were presented as medians (with 
range). A univariable linear regression model with CRAE and 
CRVE as the dependent variables was used to study possible asso-
ciations between the retinal vasculature and clinical measures. 
Pearson’s r correlation coefficient was used to test for correlations. 
The Mann-Whitney test was used to test for differences in con-
tinuous data between two groups, and Cuzick’s test for trend was 
used to test for trend in differences between several groups. Neu-
rogenic parameters from mf-ERG (mean of rings 1–6) and OCT 
were subsequently used in a multivariable linear regression model 
with CRAE and CRVE as the dependent variables. The multivari-
able analysis was adjusted for age, sex, duration of diabetes, dia-
stolic and systolic blood pressure, level of DR, HbA 1c and CRAE 
or CRVE, conversely. 
 Results 
 Baseline data included images of 449 patients. Nine 
patients had either ungradable images (n = 4) or less than 
6 detectable retinal arterioles and venules (n = 5). For the 
remaining 440 patients, median age and duration of 
T2DM were 64.0 and 10.3 years, respectively, and 66.1% 
were men. ETDRS levels were 10 (42.3%), 20 (27.5%) and 
35 (30.2%). Median CRAE and CRVE were 146.7 μm 
(range 110.4–196.0 μm) and 215.3 μm (range 160.0–290.8 
μm), respectively ( table 1 ). 
 Table 1.  Clinical characteristics (median values) of patients with T2DM overall and according to the ETDRS scale, 
levels 10, 20 and 35
Overall
(n = 440)
Level 10
(n = 186)
Level 20
(n = 121)
Level 35
(n = 133)
p 
for trend
Age, years 64.0 65 63 63 <0.01
Sex, % male 66.1 71.0 62.0 63.2 0.15
Duration of diabetes, years 10.3 9.3 10.2 13.2 <0.01
Systolic blood pressure, mm Hg 135 132 138 136 0.09
Diastolic blood pressure, mm Hg 78 77 77 78 0.81
DR, %
ETDRS level 10 42.3
ETDRS level 20 27.5
ETDRS level 35 30.2
HbA1c, % 7.0 6.8 6.9 7.3 <0.01
mf-ERG implicit time (mean of rings 1 – 6), ms 36.6 36.8 36.6 36.6 0.93
mf-ERG amplitude (mean of rings 1 – 6), nV/degree2 43.4 44.5 41.2 42.1 0.02
Retinal thickness in macula, μm 265 263 268 265 0.13
Macular GCL thickness, μm 79 79 80 79 0.91
RNFL thickness at optic disc, μm 90 90 91 88 0.54
CRAE, μm 146.7 144.5 148.0 148.2 0.12
CRVE, μm 215.3 214.5 213.2 216.6 0.04
 p for trend: Cuzick’s test for trend was used; p < 0.05 was considered statistically significantly different.
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 Patients with higher ETDRS levels of DR were youn ger 
(p < 0.01), had a longer duration of T2DM (p < 0.01), 
higher HbA 1c (p < 0.01), lower mf-ERG mean amplitudes 
of rings 1–6 (p = 0.02) and wider CRVE (p = 0.04;  table 1 ). 
On the other hand, CRAE did not significantly differ ac-
cording to the level of DR (p = 0.12). 
 In a univariable model ( table 2 ), CRAE correlated with 
age (coefficient –0.37 per year, p < 0.01), mf-ERG ampli-
tude mean of rings 1–6 (coefficient 0.12 per nanovolts/
squared degree, p = 0.03), macular GCL thickness (coef-
ficient 0.39 per micrometre GCL thickness, p < 0.01; 
 fig. 1 ), RNFL thickness at the optic disc (coefficient 0.19 
per micrometre RNFL thickness, p < 0.01) and CRVE (co-
efficient 0.37 per micrometre CRVE, p < 0.01). CRVE 
correlated with age (coefficient –0.32 per year, p = 0.03), 
macular GCL thickness (coefficient 0.34 per micrometre 
GCL thickness, p < 0.01), RNFL thickness at the optic disc 
(coefficient 0.35 per micrometre RNFL thickness, p < 
0.01;  fig. 2 ) and CRAE (coefficient 0.85 per micrometre 
CRAE, p < 0.01). Retinal vessel calibre was not correlated 
with gender, body mass index, duration of diabetes, 
HbA 1c , blood pressure, dyslipidaemia, presence of other 
diabetic complications (i.e. presence of nephropathy and 
neuropathy) or any other OCT and mf-ERG parameters. 
 In an overall multivariable linear regression model ( ta-
ble 2 ), CRAE was associated with age (coefficient –0.19 
per year, p = 0.04), sex (coefficient –2.94 for females vs. 
males, p = 0.01), macular GCL thickness (coefficient 0.27 
per micrometre GCL thickness, p < 0.01) and CRVE (co-
efficient 0.37 per micrometre CRVE, p < 0.01). CRVE was 
correlated with sex (coefficient 6.59 for females vs. males, 
p < 0.01), macular retinal thickness (coefficient –0.07 per 
micrometre retinal thickness, p = 0.04), RNFL thickness 
at the optic disc (coefficient 0.32 per micrometre RNFL 
thickness, p < 0.01) and CRAE (coefficient 0.86 per mi-
crometre CRAE, p < 0.01). 
 In clinical terms, each year increment of age was cor-
related with a decrease in CRAE by –0.19 μm, female gen-
der was associated with a decrease in CRAE by –2.94 μm, 
each micrometre increment of macular GCL thickness 
was correlated with an increase in CRAE by 0.27 μm and 
each micrometre increment of CRVE was correlated with 
an increase in CRAE by 0.37 μm. Regarding retinal venu-
lar calibre, male gender was correlated with an increase in 
CRVE by 6.59 μm, each micrometre increment of macu-
lar retinal thickness was associated with an decrease in 
CRVE by 0.07 μm, each micrometre increment of RNFL 
thickness at the optic disc was associated with an increase 
in CRVE by 0.32 μm, and each micrometre increment of 
CRAE was correlated with an increase in CRVE by 0.86 
μm. 
 Table 2.  Overall univariable and multivariable linear regression models with CRAE and CRVE as the dependent variables
CRAE  CRVE
univariable 
model
multivariable 
model
un ivariable 
model
multivariable 
model
Age –0.37 (<0.01) –0.19 (0.04) –0.32 (0.03) 0.06 (0.66)
Sex –1.98 (0.15) –2.94 (0.01) 3.14 (0.13) 6.59 (<0.01)
Duration of diabetes –0.14 (0.21) –0.12 (0.23) –0.07 (0.69) 0.10 (0.51)
Systolic blood pressure –0.08 (0.07) –0.03 (0.44) –0.001 (0.98) 0.02 (0.77)
Diastolic blood pressure –0.08 (0.25) –0.12 (0.07) 0.09 (0.41) 0.17 (0.09)
DR 1.65 (0.21) –0.02 (0.99) 3.26 (0.10) 2.74 (0.12)
HbA1c 0.54 (0.41) 0.45 (0.41) 0.61 (0.54) –0.57 (0.50)
mf-ERG implicit time –0.10 (0.80) 0.09 (0.78) 0.01 (0.98) 0.24 (0.62)
mf-ERG amplitude 0.12 (0.03) 0.04 (0.34) 0.09 (0.25) 0.02 (0.83)
Macular retinal thickness –0.02 (0.43) 0.002 (0.93) –0.04 (0.35) –0.07 (0.04)
Macular GCL thickness 0.39 (<0.01) 0.27 (<0.01) 0.34 (<0.01) –0.18 (0.20)
RNFL thickness at optic disc 0.19 (<0.01) –0.10 (0.12) 0.35 (<0.01) 0.32 (<0.01)
CRVE 0.37 (<0.01) 0.37 (<0.01)
CRAE 0.85 (<0.01) 0.86 (<0.01)
 The multivariable model includes age, sex, duration of diabetes, systolic and diastolic blood pressure, DR, HbA1c, mean mf-ERG 
implicit time, mean mf-ERG amplitude, macular retinal thickness, macular GCL thickness, RNFL thickness at the optic disc, and CRVE 
or CRAE. Figures in parentheses indicate p values; p < 0.05 was considered statistically significantly different. 
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 Discussion 
 In this cross-sectional study of patients with T2DM 
without DR or with only early stages of DR, retinal vessel 
calibre was independently associated with structural, but 
not functional, retinal neurodegeneration. Retinal arte-
riolar calibre was positively correlated with macular GCL 
thickness, and retinal venular calibre correlated negative-
ly with macular retinal thickness and positively with 
RNFL thickness at the optic disc.
 The impairment of neurovascular coupling preceded 
the overt micro-angiopathy which could be detected by 
funduscopic examination. Endothelial cells, glial cells, 
neural cells, and pericytes are all interacting and partici-
pating in the neurovascular unit and may therefore con-
tribute to changes in the retinal vasculature and retinal 
vessel calibre  [6] . Wider arterioles may originate from 
high blood flow and increased oxygen resources. Corre-
spondingly, wider retinal venular calibres may be caused 
by impaired vascular autoregulation and ischaemia or ap-
pear because of increased blood pressure. 
 Previous cross-sectional clinical studies found that 
wider retinal venular diameters were associated with 
presence of DR, and narrower arteriolar calibres were 
correlated with severer DR  [18, 23–26] . In contrast, pro-
spective studies showed controversial results. In this re-
gard, whereas Broe et al.  [14] reported that narrower ret-
inal arterioles were able to predict proliferative DR, 
Cheung et al.  [27] and Alibrahim et al.  [28] found that a 
wider arteriolar calibre was predictive of the development 
of DR. Prospective studies also showed that wider venular 
calibres were associated with progression of DR or could 
predict incident proliferative DR  [29, 30] . This has even 
been prospectively demonstrated in a long-term follow-
up study  [14] . 
 In the present study we provide evidence that CRAE 
correlated positively with macular GCL thickness in early 
stages of DR. This has not been previously reported and 
suggests a unique relationship between the macular gan-
glion cells and the retinal arteriolar diameters. The fol-
low-up of the patients included in the EUROCONDOR 
study could answer the question whether this relationship 
is maintained in more advanced stages of DR. 
 We have found a negative correlation between CRVE 
and macular retinal thickness. In contrast, in a smaller 
study Harrison et al.  [18] did not find correlations be-
tween retinal thickness and retinal vessel calibres in pa-
tients with T2DM and no, mild or moderate DR. Overall, 
our findings suggest that venules are impaired earlier 
than arterioles in DR and that this event is related to neu-
rodegeneration. In addition, our results point to CRVE as 
a potential biomarker of retinal neurodegeneration. 
 CRVE was also positively associated with RNFL thick-
ness at the optic disc. In an earlier study by van Dijk et al. 
 [31] , thinning of RNFL was found in 25 patients with 
minimal DR as compared to participants with no diabe-
tes. However, these measurements were conducted at the 
central and peripheral macula and, thus, do not compare 
directly with our finding. As with the association between 
CRAE and macular GCL, we speculate that our finding 
80
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 Fig. 1. Correlation between CRAE and GCL thickness among 440 
patients with T2DM and no or minimal DR (r = 0.21, p < 0.01). 
 Fig. 2. Correlation between CRVE and RNFL thickness at the optic 
disc among 440 patients with T2DM and no or minimal DR (r = 
0.17, p < 0.01). 
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could indicate a link between vascular changes and neu-
rodegeneration in early DR. Future studies will tell wheth-
er this connection is also found in the more advanced 
stages of DR. 
 In our study, we have identified novel and specific as-
sociations between non-invasive vascular markers and 
early neurodegeneration in a large group of patients with 
T2DM with no or early DR. Future studies will be needed 
to establish the cause-effect relationship between retinal 
vascular calibres and neurodegeneration in early DR. 
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